Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
06 08 2019
Historique:
pubmed: 18 6 2019
medline: 19 5 2020
entrez: 18 6 2019
Statut: ppublish

Résumé

Bridge to transplantation (BTT) with left ventricular assist devices (LVADs) is a mainstay of therapy for heart failure in patients awaiting heart transplantation (HT). Criteria for HT listing do not differ between patients medically managed and those mechanically bridged to HT. The objectives of the present study were to evaluate the impact of BTT with LVAD on posttransplantation survival, to describe differences in causes of 1-year mortality in medically and mechanically bridged patients, and to evaluate differences in risk factors for 1-year mortality between those with and those without LVAD at the time of HT. Using the United Network of Organ Sharing database, we identified 5486 adult, single-organ HT recipients transplanted between 2008 and 2015. Patients were propensity matched for likelihood of LVAD at the time of HT. Kaplan-Meier survival estimates were used to assess the impact of BTT on 1- and 5-year mortality. Logistic regression analysis was used to evaluate the odds ratio of 1-year mortality for patients BTT with LVAD compared with those with medical management across clinically significant variables at various thresholds. Early mortality was higher in mechanically bridged patients: 9.5% versus 7.2% mortality at 1 year (P<0.001). BTT patients incurred an increased risk of 1-year mortality with an estimated glomerular filtration rate of 40 to 60 mL·min Bridge to HT with LVAD, although necessary because of organ scarcity and capable of improving wait list survival, confers a significantly higher risk of early posttransplantation mortality. Patients bridged with mechanical support may require more careful consideration for transplant eligibility after LVAD placement.

Sections du résumé

BACKGROUND
Bridge to transplantation (BTT) with left ventricular assist devices (LVADs) is a mainstay of therapy for heart failure in patients awaiting heart transplantation (HT). Criteria for HT listing do not differ between patients medically managed and those mechanically bridged to HT. The objectives of the present study were to evaluate the impact of BTT with LVAD on posttransplantation survival, to describe differences in causes of 1-year mortality in medically and mechanically bridged patients, and to evaluate differences in risk factors for 1-year mortality between those with and those without LVAD at the time of HT.
METHODS
Using the United Network of Organ Sharing database, we identified 5486 adult, single-organ HT recipients transplanted between 2008 and 2015. Patients were propensity matched for likelihood of LVAD at the time of HT. Kaplan-Meier survival estimates were used to assess the impact of BTT on 1- and 5-year mortality. Logistic regression analysis was used to evaluate the odds ratio of 1-year mortality for patients BTT with LVAD compared with those with medical management across clinically significant variables at various thresholds.
RESULTS
Early mortality was higher in mechanically bridged patients: 9.5% versus 7.2% mortality at 1 year (P<0.001). BTT patients incurred an increased risk of 1-year mortality with an estimated glomerular filtration rate of 40 to 60 mL·min
CONCLUSIONS
Bridge to HT with LVAD, although necessary because of organ scarcity and capable of improving wait list survival, confers a significantly higher risk of early posttransplantation mortality. Patients bridged with mechanical support may require more careful consideration for transplant eligibility after LVAD placement.

Identifiants

pubmed: 31203669
doi: 10.1161/CIRCULATIONAHA.118.036932
pmc: PMC8223200
mid: NIHMS1532694
doi:

Substances chimiques

Cardiovascular Agents 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-469

Subventions

Organisme : NHLBI NIH HHS
ID : K08 HL146964
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Eur J Cardiothorac Surg. 2005 Feb;27(2):222-5
pubmed: 15691674
Am J Transplant. 2018 Jun;18(6):1461-1470
pubmed: 29136325
J Thorac Cardiovasc Surg. 2010 Jul;140(1):174-81
pubmed: 20447659
J Thorac Cardiovasc Surg. 2008 Sep;136(3):774-7
pubmed: 18805284
Circulation. 2013 Jan 29;127(4):452-62
pubmed: 23271796
Circ Heart Fail. 2018 Jun;11(6):e004670
pubmed: 29903893
J Heart Lung Transplant. 2011 Aug;30(8):854-61
pubmed: 21571550
J Thorac Cardiovasc Surg. 2003 Oct;126(4):1188-90
pubmed: 14566269
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
J Am Coll Cardiol. 2009 Jan 20;53(3):264-71
pubmed: 19147043
J Heart Lung Transplant. 2015 Dec;34(12):1495-504
pubmed: 26520247
J Heart Lung Transplant. 2015 Jan;34(1):89-99
pubmed: 25444372
Eur J Cardiothorac Surg. 2008 Aug;34(2):295-300
pubmed: 18539472
Transplantation. 2010 Aug 27;90(4):444-50
pubmed: 20622755
JAMA Cardiol. 2017 Jan 1;2(1):98-99
pubmed: 27806174
Circ Heart Fail. 2014 Jan;7(1):68-75
pubmed: 24214901
J Heart Lung Transplant. 2018 Dec;37(12):1433-1442
pubmed: 30206023
J Thorac Cardiovasc Surg. 2009 Dec;138(6):1425-32.e1-3
pubmed: 19931672
Circ Heart Fail. 2018 Apr;11(4):e004586
pubmed: 29666073
J Heart Lung Transplant. 2014 Apr;33(4):327-40
pubmed: 24661451
Ann Thorac Surg. 2018 Mar;105(3):770-777
pubmed: 29289367
J Thorac Cardiovasc Surg. 2013 Feb;145(2):575-81
pubmed: 23321132
ASAIO J. 2018 Jan/Feb;64(1):43-51
pubmed: 28777136
Interact Cardiovasc Thorac Surg. 2017 Aug 1;25(2):212-217
pubmed: 28459983
J Am Heart Assoc. 2018 May 17;7(11):
pubmed: 29773577

Auteurs

Lauren K Truby (LK)

Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC (L.K.T.).

Maryjane A Farr (MA)

Division of Cardiology, Department of Medicine (M.A.F., A.R.G., R.G., S.W.R., F.L., V.K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

A Reshad Garan (AR)

Division of Cardiology, Department of Medicine (M.A.F., A.R.G., R.G., S.W.R., F.L., V.K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Raymond Givens (R)

Division of Cardiology, Department of Medicine (M.A.F., A.R.G., R.G., S.W.R., F.L., V.K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Susan W Restaino (SW)

Division of Cardiology, Department of Medicine (M.A.F., A.R.G., R.G., S.W.R., F.L., V.K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Farhana Latif (F)

Division of Cardiology, Department of Medicine (M.A.F., A.R.G., R.G., S.W.R., F.L., V.K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Hiroo Takayama (H)

Division of Cardiothoracic Surgery, Department of Surgery (H.T., Y.N., K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Yoshifumi Naka (Y)

Division of Cardiothoracic Surgery, Department of Surgery (H.T., Y.N., K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Koji Takeda (K)

Division of Cardiothoracic Surgery, Department of Surgery (H.T., Y.N., K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Veli K Topkara (VK)

Division of Cardiology, Department of Medicine (M.A.F., A.R.G., R.G., S.W.R., F.L., V.K.T.), Columbia University College of Physicians and Surgeons, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH